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First case of B ALL with KMT2A-MAML2
rearrangement: a case report
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Regis Costello4 and Jean Gabert1,2
Abstract
Background: A large number of chromosomal translocations of the human KMT2A gene, better known as the MLL
gene, have so far been characterized. Genetic rearrangements involving KMT2A gene are frequently involved in
lymphoid, myeloid and mixed lineage leukemia. One of its rare fusion partners, the mastermind like 2 (MAML2) gene
has been reported in four cases of myeloid neoplasms after chemotherapy so far: two acute myeloid leukemias (AML)
and two myelodysplasic syndrome (MDS), and two cases of secondary T-cell acute lymphoblastic leukemia (T-ALL).
Case presentation: Here we report the case of a KMT2A - MAML2 fusion discovered by Next-Generation Sequencing
(NGS) analysis in front of an inv11 (q21q23) present in a 47-year-old female previously treated for a sarcoma in 2014,
who had a B acute lymphoid leukemia (B ALL).
Conclusion: It is, to our knowledge, the first case of B acute lymphoblastic leukemia with this fusion gene. At the
molecular level, two rearrangements were detected using RNA sequencing juxtaposing exon 7 to exon 2 and exon 9
to intron 1–2 of the KMT2A and MAML2 genes respectively, and one rearrangement using Sanger sequencing
juxtaposing exon 8 and exon 2.
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Background
Over 70 KMT2A partner genes have been reported so
far in the literature. Translocation of the KMT2A gene,
better known as the MLL gene, is present in 7–10% of B
acute lymphoblastic leukemias, AFF1 (or AF4) being the
most frequent partner gene. The prognosis of B acute
lymphoblastic leukemias (B ALL) with KMT2A gene
translocations are usually poor, especially with KMT2A-
AFF1 fusions [1, 2]. One of its rare partner genes,
mastermind like 2 (MAML2) gene has been reported in
four cases of myeloid neoplasms after chemotherapies:
two cases of acute myeloid leukemia (AML) and two
cases of myelodysplasic syndromes (MDS) [3]. Second-
ary acute lymphoid leukemia is a well-documented oc-
currence following topoisomerase II inhibitors and
cyclophosphamide chemotherapy and/or radiotherapy.
The premise that radiotherapy as well as chemotherapy
are inducing t(4;11)(q21;q23) was raised before [4].
Indeed two cases of secondary T-cell acute lympho-
blastic leukemia with KMT2A-MAML2 transcripts have
been described in two adolescent leukemia patients [5].
At the molecular level, much progress has been made in
the identification of fusion transcripts and finding new al-
ternatives to fluorescent in situ hybridization (FISH). In
fact, the identification of fusion transcripts is possible with
the Next-Generation Sequencing (NGS) technologies,
such as RNA-Sequencing [6]. At the moment, this method
seems to be the best for identifying new gene fusion tran-
scripts, and is steadily improving [7]. In this case, we high-
light one of the limitations of this powerful tool.
Case presentation
Patient’s history and clinical features
A 47-year-old female, with morbid obesity and hyper-
trophic cardiopathy, presented to hospital in cardiopul-
monary arrest most likely due to a cardiac rhythm
disturbance. During hospitalization in the cardiac sec-
tion, laboratory analysis revealed anemia (Hb 105 g/L),
thrombocytopenia (59 × 109 platelets/L) and a total
leukocyte count of 6.2 × 109/L with 1% blast cells. Bone
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marrow aspiration showed hyper cellular marrow with
agranular leukemic cells (35%). The examination of the
bone marrow morphology revealed dysplasia on the
three cell lineages. Flow cytometric immunophenotyping
of bone marrow identified blast cells that were positive
for cCD79a, CD22, CD19 and CD45, and negative for
CD10. There was a history of high-grade thoracic sar-
coma in the previous year, treated with surgical resec-
tion, three cycles of chemotherapy (Doxorubicin/
Ifosfamide) and then radiotherapy. This patient had sev-
eral thrombocytopenic episodes and encephalopathy due
to ifosfamide. Hence, the patient was diagnosed with B
ALL with a very poor prognosis secondary to the sar-
coma treatment. Induction chemotherapy with cytara-
bine and anthracycline was started, but only one cycle of
chemotherapy was achieved due to general deterioration,
leading to an admission to intensive care. The patient
deteriorated rapidly and passed away.
Patient’s molecular features
Bone marrow conventional cytogenetic analysis showed
a complex hyperdiploid karyotype with multiple struc-
tural and numerical abnormalities including 2p11 dele-
tion and duplication of the inverted chromosome 11.
Based on R-banding analysis, the karyotype was inter-
preted as 63, XX, +del(2)(p11),+5,+6,+7,+8,+9,+9,
+10,+10,+11,+12,+13,+14,+15,+19,+20,+22[22]/46, XX
[4] (Fig. 1c). FISH analysis was performed on bone mar-
row aspirate (Fig. 1a) using a LSI KMT2A break apart
probe (Vysis, Abbott Molecular Inc.). It revealed the
presence of one normal chromosome and two inverted 11
chromosomes, each carrying a KMT2A gene rearrangement
with an unknown fusion partner, in four metaphases and in
58/100 nuclei (Fig. 1b).
RNA sequencing (RNA-Seq) has been used to identify
gene fusions on RNA extracted from the patient’s blood.
Venous blood (10 mL) was collected in EDTA tubes
from the patient and PBMC were isolated by erythro-
cytes lysis (Buffer EL, Qiagen). Total RNA was extracted
from 1 × 107 cells using Trizol Reagent (life technolo-
gies). For paired-end RNA-Seq, we have used the TruSeq
RNA Library Prep Kits followed by paired-end cluster
generation and sequencing using the 2 × 150 NextSeq
500 high output kit and the Illumina NextSeq 500 se-
quencing platform. The first variant (Var 1) corre-
sponded to the fusion of the exon 7 of KMT2A and the
exon 2 of MAML2 as described previously [3]. For the
second variant (Var 2), the data revealed that the fusion
point was within the exon 9 of KMT2A gene and within
the intron 1–2 of MAML2 gene. To validate these RNA-
Seq results, we have performed RT-PCR with specific
primers localized on exon 7 or exon 8 of KMT2A gene
and intron 1–2 or exon 2 of MAML2 gene and Sanger
sequencing (Fig. 2). The results had confirmed the
presence of the two variants but had showed unexpect-
edly a new variant (Var 3). This fusion gene corre-
sponded to the rearrangement juxtaposing exon 8 and
exon 2 of the KMT2A and MAML2 genes respectively
and was detected with a higher expression level than the
other variants (Fig. 3).
Discussion and conclusions
Here, we reported the first case of a B ALL in a 47 years
old woman bearing a KMT2A-MAML2 rearrangement
detected by NGS RNA analysis. As a result, KMT2A-
MAML2 rearrangement can be found in several types of
acute leukemia. Moreover, we have detected two new
variants of this fusion transcript based on exon fusion
analysis. In fact, RNA sequencing juxtaposing exons 9 of
the KMT2A to intron 1–2 of the MAML2 gene, and
exon 8 of the KMT2A to exon 2 of the MAML2 gene,
have not previously been reported.
Three hypotheses may explain these molecular findings.
Either three different breakpoints exist, or/and it is the re-
sult of alternative splicing. Indeed, mRNA precursors could
lead to the production, via alternative splicing, of a fusion
transcript exon 8 of the KMT2A gene to exon 2 of the
MAML2 gene and exon 7 of the KMT2A gene to exon 2 of
the MAML2 gene. Alternative splicing are mechanisms in-
voked to play an important role in influencing the mutation
effect [8]. The possibility of exons’ skipping or inclusion are
almost unlimited, thus, any gene could potentially lead to
tens or hundreds of distinctive transcripts. Moreover, we
ruled out the possibility of a pre-mRNA by RNA sequen-
cing and PCR. In fact, pre-mRNA contains both introns
and exons, and requires splicing of introns to produce the
final mRNA molecule containing only exons. In our case,
after RNA sequencing and PCR only intron 1–2 of the
MAML2 gene persists and this variant was found in signifi-
cant quantity. Each of the putative fusion transcripts was
then translated into predicted amino acid sequences and
each of the putative fusion proteins characterized. Two of
the three variants (Var 2 and Var 3) contained in-frame
stops and are unlikely to encode functional proteins. For
the third variant (Var 1), the transcript contained the
boundary exons and generated putative fusion transcript.
Furthermore, this case highlights one of the limitations
of NGS. In fact, two different KMT2A-MAML2 gene fu-
sions were found by NGS technology, but the major fu-
sion variant, juxtaposing exons 8 of the KMT2A gene
and exon 2 of the MAML2 gene, was not detected. NGS
methods have the ability to detect a wide array of muta-
tion types, which is mostly limited by the need to know
all potential off-target capture regions and to properly
process the raw data generated by the sequencer [9]. We
had to use Sanger sequencing with specific primers to
detect this third variant of KMT2A-MAML2 gene fusion,
which was clearly demonstrated on the PCR gel (Fig. 2).
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Fig. 2 RT-PCR analysis of KMT2A-MAML2 fusion gene. RT-PCR for the KMT2A-MAML2 fusion was performed from patient’s RNA. 1 μg total RNA
were reverse-transcribed into cDNA in a 20 μl total volume using random hexamer primers according to EAC protocol (Gabert et al.,2003). PCR
reactions contained 1× PCR buffer (Applied Biosystems), 20 nmol dNTPs (Applied Biosystems), 300 nM primer of each primer, 1.25 units of
AmpliTaq Gold polymerase (Applied Biosystems), and 5 μl of cDNA in a 50-μl reaction volume. Specific primers were used and were localized
on exon 8 of KMT2A (5′-GTCCAGAGCAGAGCAAACAG-3′) and intron 1–2 of MAML2 (5′-TCCCATCTCCAAGTCTCAGC-3′) (Lane 1), on exon 8 of
KMT2A and exon 2 of MAML2 (5′-GAGTCTCTCCTGGCTCCTTC-3′) (Lane 2) and on exon 7 of KMT2A (5′-ATCCTGCCCCAAAGAAAAGC-3′) and exon 2
of MAML2 (Lane 3). PCR products were analyzed with Agilent DNA 1000 kit using the 2100 bioanalyzer
Fig. 1 Cytogenetic analysis at initial diagnosis. Ish inv. (11) (q21, 5’MLL+)(q23, 3’MLL+) ×2 [4].nucish (Mllx3, 5’MLLsep3’MLLx2) [58/100]. FISH study
using a LSI KMT2A break apart probe (Vysis, Abbott Molecular Inc.): (a) an interphase cell showing one non-rearranged orange/green signal fusion
and two centomeric (red) and two telomeric (green) separate signals, (b) a metaphase cell showing a normal chromosome 11 and two inverted
chromosome 11, (c) karyotype from bone marrow aspirate showing complex chromosome abnormalities
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Concerning the development of secondary leukaemia
following chemo-radiotherapy for sarcoma, it is known
that chemo-radiotherapy administered for a primary
cancer will increase the risk of secondary neoplasms
[10]. Alkylating agents have been reported as affecting
the radiation therapy-associated risk for secondary ma-
lignancies [11]. However, in this case, the speed of devel-
opment of a secondary leukemia is unusual. Alkylating
agent/radiotherapy-related leukemia has a mean latency
period of 5–7 years, are often preceded by a myelodys-
plastic phase and are frequently associated with complex
karyotypes, whereas acute secondary leukaemia after
treatment with DNA topoisomerase II inhibitors has a
relatively short latency period (several months to 3 years)
and is associated with chromosomal translocation in-
volving 11q23, respectively the KMT2A gene [12, 13].
To conclude, clinical outcomes of KMT2A-associated
leukemias are often unfavorable and identification of a
KMT2A partner could lead to new therapeutic strategies.
Moreover, bringing to light several variants of a fusion
transcript, such as the KMT2A-MAML2 gene, is import-
ant in the follow-up of residual disease.
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